About Us
General Oligo ("GO") is a team of scientists and engineers dedicated to advancing nucleic acid technology through precision design, sustainable manufacturing, and open collaboration. Founded in early 2025, we combine expertise in nucleic acid chemistry, oligonucleotide synthesis, and synthetic biology with a commitment to developing practical, reliable products for life science research.
Our Products
Biomaterials
Advanced materials for scientific innovation.
Research Kits
Precision tools for the modern researcher.
Coming Soon.
Please subscribe to our newsletter for more information and updates.
Our Services
We provide expert support and guidance from early research through technology translation.
Oligonucleotide Synthesis
GO advises on the full spectrum of oligonucleotide synthesis workflows—from experimental design and testing to data analysis, quality control, and manufacturing readiness. We help teams build reliable, reproducible processes that align with both research and production goals.
Technical Due Diligence
Our team conducts independent assessments of emerging technologies, reviewing technical feasibility, experimental design, and intellectual-property landscapes. These evaluations help investors, startups, and research groups de-risk early innovation and focus resources effectively.
Platform Development
We support organizations developing new platforms that incorporate nucleic acids, whether it be chemical, enzymatic, or hybrid approaches. Our guidance spans architecture design, proof-of-concept planning, and technical integration across diverse life-science applications.
Commercialization Strategy
Drawing on our experience as founders and entrepreneurs, we help clients connect technical innovation to practical business outcomes. We advise on product positioning, partnership strategy, and go-to-market planning for nucleic acid-based technologies and related life science tools.
Working with General Oligo
We combine deep technical understanding with real-world startup and translational experience. Our background spans enzymatic and chemical oligonucleotide synthesis, platform design, and commercialization of life science technologies—allowing us to bridge the gap between innovation and operational execution.
Biotech startups, academic groups, investors, and life science companies developing or evaluating new research tools, materials, or platform technologies.
Actionable insight. Each engagement produces clear recommendations—whether it’s a synthesis design, feasibility assessment, or commercialization plan—tailored to your stage of development.
Submit a brief inquiry describing your objectives. We’ll schedule a short introduction call, define the scope of work, and provide a transparent proposal and quote.